Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the original post here:

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Owned

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patients immune system to attack cancer. But immunotherapies dont work in all patients, and researchers have been searching for ways to increase their effectiveness.

Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia. Evidence also suggests that the new approach could be safer than one of the most recent cellular immunotherapies to be approved by the FDA, called CAR-T cell therapy, in which the immune systems T cells are engineered to target tumor cells. Cell-based immunotherapies are most commonly used against blood cancers but can be harnessed against some solid tumors as well, such as prostate and lung tumors and melanoma.

The study appears online in the journal Blood.

In the new research, the scientists have harnessed the technology used to engineer CAR-T cells and, instead of modifying specialized immune cells called T cells, they have used similar technology to alter different immune cells called natural killer (NK) cells. The resulting immunotherapy combines the benefits of both strategies and may reduce the side effects that are sometimes seen in CAR-T cell therapy. In some patients, for example, CAR-T cell therapy causes a cytokine storm, a life-threatening overreaction of the immune system.

Immunotherapies show great promise for cancer therapy, but we need to make them more effective and more safe for more patients, said co-senior authorTodd A. Fehniger, MD, PhD, a professor of medicine. This combined approach builds on the treatment strategy that we developed for leukemia patients using natural killer cells. We can supercharge natural killer cells to enhance their ability to attack cancer cells. And at the same time, we can use the genetic engineering approaches of CAR cell therapy to direct the natural killer cells to a tumor target that would normally be overlooked by NK cells. It fundamentally changes the types of cancer that NK cells could be used to treat, both additional blood cancers and potentially solid tumors as well.

In past work, Fehniger and his colleagues showed that they could collect a patients own NK cells, expose the cells to a specific recipe of chemical signals that prime the cells to attack tumors, and then return the primed cells to patients for therapy. This chemical exposure is a sort of basic training for the cells, according to the investigators, preparing the NK cells to fight the cancer. When the cells are then returned to the body, they remember their training, so to speak, and are more effective at targeting the tumor cells. Because their training has given the NK cells a memory of what to do when they encounter tumor cells, the researchers dubbed them memory-like NK cells.

In small clinical trials conducted atSiteman Cancer Centerat Barnes-Jewish Hospital and Washington University School of Medicine, such cells were effective in putting some patients with leukemia into a lasting remission, but they didnt work for everyone. Some tumor cells still evaded the memory-like NK cells, despite the cells basic training. To help the cells find the tumor cells, so their basic training can kick in and kill the correct target, the researchers modified the memory-like NK cells with the same CAR (chimeric antigen receptor) molecule that is typically used to target T cells to tumor cells. The CAR molecule is flexible and can be modified to direct the cells to different tumor types, depending on the proteins on the surfaces of the cancer cells.

The resulting hybrid cells were more effective in treating mice with leukemia than memory-like NK cells alone, leading to longer survival for mice treated with CAR memory-like NK cells. The researchers also found the therapy to be effective despite the fact that the mice were given relatively low doses of the cells.

One aspect of this study I find most exciting is how nicely these hybrid NK cells expand in the mice to respond to their tumors, said co-senior authorMelissa Berrien-Elliott, PhD, an instructor in medicine. We can provide a tiny dose and see an incredible amount of tumor control. To me, this highlights the potency of these cells, as well as their potential to expand once in the body, which is critical for translating these findings to the clinic.

Fehniger also pointed out that an advantage of NK cells in general and for biological reasons that the scientists are still working to understand NK cells dont trigger a dangerous immune response or the long-term side effects that T-cell therapy can cause in attacking the patients healthy tissues, a condition called graft-versus-host disease.

In all of the clinical trials exploring any type of NK cells, we dont see the troublesome side effects of cytokine release syndrome or neurotoxicity that we see with CAR-T cells that can profoundly affect patients, Fehniger said. These side effects can be life-threatening and require intensive care. Were still working to understand how NK cells are different. But if you can get the benefits of CAR-T cells with few if any of the side effects, thats a reasonable line of research to pursue. Another benefit of this safer therapy is the potential to give these cells to patients at an earlier stage in their disease, rather than using them as a last resort.

Other groups have developed CAR-NK cells, but a major difference is that other groups NK cells came from donated cord blood or induced stem cells, rather than adult donors or the patients themselves.

The other groups have artificially differentiated stem cells into something that resembles an NK cell, Fehniger said. With that strategy, theres no guarantee that those cells will have all the properties of typical mature NK cells. In contrast, were starting with adult NK cells, so were more confident that they will have all the inherent properties and behavior of adult NK cells, which we have already shown to be effective in certain types of cancer patients, especially those with leukemia. Inducing memory properties adds to their persistence and effectiveness against many cancer types.

Over the next several years, we would like to be able to scale up this process to produce enough cells for a first-in-human clinical trial, and investigate their effectiveness in different types of human blood cancers, he said.

Reference: Gang, et al. (2020). CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. DOI: https://doi.org/10.1182/blood.2020006619

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers - Technology Networks

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistryhave identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.

A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity.

BACKGROUND

Immunotherapies using PD1 blockade have transformed the way people with difficult cancers are treated. Currently, PD1 blockade combined with chemotherapy is approved for recurrent or metastatic head and neck cancer, giving people whose disease would have otherwise been seen as a death sentence another option. However, response rates are not very high and response duration is relatively short, indicating that this type of cancer might be resistant to PD1 blockade.

To help overcome immunotherapy resistance, UCLA researchers have been studying the role of cancer stem cells and the protein BMI1. Growing evidence suggests cancer stem cells might be responsible for such resistance, as well as for relapse or reoccurrence, and BMI1, which functions in several cancers, including head and neck, has been found to control cancer stem cells self-renewal. Targeting cancer stem cells may be critical for improving the efficacy of immunotherapy and preventing tumor relapse.

METHOD

The team used a mouse model of head and neck squamous cell carcinoma that fully mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. They then tested whether BMI1 cancer stem cells could be eradicated by PD1 blockadebased combination therapy using both pharmacological and genetic inhibition of BMI1. They found that inhibiting BMI1 not only helped eliminate the BMI1 cancer stem cells but also enhanced PD1 blockade by activating tumor cellintrinsic immunity, which inhibited metastatic tumor growth and prevented tumor relapse.

IMPACT

Many people with advanced head and neck cancers who are treated with PD1 blockade and chemotherapy eventually see their cancer return and become resistant to the therapy. This preclinical study provides an important foundation for developing a new PD1 blockadebased combination therapy with BMI1 inhibitors that have the potential to help overcome resistance to the immunotherapy.

AUTHORS

The senior author is Dr. Cun-Yu Wang, professor and chair of oral biology at the UCLA School of Dentistry and a member of the UCLAs Jonsson Comprehensive Cancer Center, Samueli School of Engineering and Broad Stem Cell Research Center. The lead author is Lingfei Jia, an assistant project scientist in oral biology at the School of Dentistry and Jonsson Cancer Center. Wuchang Zhang, an assistant project scientist in oral biology, is also an author.

JOURNAL

The study ispublished onlinein the journal Cell Stem Cell.

FUNDING

The work was supported by grants from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.

See original here:

Researchers ID new target in drive to improve immunotherapy for cancer - UCLA Newsroom

This article was originally published here

Stem Cell Rev Rep. 2020 Jul 21. doi: 10.1007/s12015-020-10004-x. Online ahead of print.

ABSTRACT

Nearly 500000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents antiviral and anti-inflammatory molecules have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.

PMID:32696426 | DOI:10.1007/s12015-020-10004-x

View original post here:

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy - DocWire News

In oncology news this week, the FDA accepted a supplemental New Drug Application for selinexor(Xpovio) as treatment of patients with relapsed or refractory multiple myeloma who had received at least 1 prior line of therapy. Meanwhile, theFDA granted clearance for the cancer drug abivertinib to be investigated in a phase 2 study as treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).

This week Targeted Oncology hosted a tweet chat with Alexander N. Shoushtari, MD, of Memorial Sloan Kettering Cancer Center, to discussion the case of a 52-year-old woman withBRAF-mutant metastatic melanoma. Following the tweet chat, Shoushtari continued the discussion in an interview.

Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML

The risk of relapse or death was reduced by 61% with the use of sorafenib maintenance therapy compared with placebo following allogeneic hematopoietic stem cell transplantation in patients withFLT3-ITDpositive acute myeloid leukemia, according to the results of the phase 2 SORMAIN trial.

Ruxolitinib Reduces Spleen Size in Patients With Myelofibrosis and Low-Platelet Counts

Ruxolitinib, the JAK1/2 inhibitor, induced significant spleen responses in patients with myelofibrosis, both with general disease and in patients with low platelet counts, according to results from the phase 3b JUMP study.

Pivotal Phase 3 Trial Initiated to Study Promising Cabozantinib/Atezolizumab Combo in Advanced RCC

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

CLR 131 Induces Encouraging Responses in Relapsed/Refractory LPL and WM

CLR 131 induced an objective response rate of 100% as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenstrms macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

Avelumab Plus TG4001 Shows Promising Efficacy in HPV16-Positive Metastatic Cancers

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies, a phase 1b/2 clinical trial showed.

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia in this episode of Targeted Oncology Case Based Peer Perspectives series.

Analyzing the Importance of Biomarker Testing and MSI Status in mCRC

Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate 142 trial.

Limited Toxicity Seen With Leronlimab in Mild to Moderate COVID-19

Treatment with leronlimab in patients with mild to moderate symptoms of respiratory illness from COVID-19 caused fewer serious adverse events when compared with placebo, according to safety results from a phase 2 clinical trial.

Study Shows Disparities, Effects of Treatment for Patients With Cancer and COVID-19

Data from a treatment utilization study revealed racial disparities in treatments for COVID-19 as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with COVID-19.

Go here to see the original:

Trending News on Targeted Oncology, Week of July 24, 2020 - Targeted Oncology

NEW YORK, July 22, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05773305/?utm_source=PRN

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%. Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion marketThe instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems.The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment.

They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research. By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells.The human cells segment includes stem cells and differentiated cells.

The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market.The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion marketNorth America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Breakdown of primariesThe study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: By Company Type Tier 1- 70%, Tier 2- 20% and Tier 3 - 10% By Designation C level Executives- 30%, Directors- 20%, Others - 50% By Region North America - 35%, Europe - 24%, APAC 25%, RoW- 16%

The cell expansion market is dominated by a few globally established players such as Thermo Fisher Scientific, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning, Inc. (US), Merck KGaA (Germany), Sartorius Stedim Biotech (France), Getinge AB (Sweden) Terumo Corporation (Japan), Miltenyi Biotec (Germany), PromoCell GmbH (Germany), Takara Bio Inc. (Japan), Solida Biotech GmBH (Germany), HiMedia Laboratories (India), Getinge AB, REPROCELL Inc. (Japan), Kohjin-Bio (Japan), Pierre Gurin (France), Cellexus Ltd.(UK), Eppendorf AG (Germany), CellGenix GmbH (Germany), iXCells Biotechnologies (US), Neuromics (US), Celltainer Biotech B.V. (Netherlands), and G&G Technologies (US).

Research Coverage:The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users).The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Key Benefits of Buying the Report:The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.

The report also helps stakeholders understand the pulse of the cell expansion market and provides them information on key market drivers, restraints, challenges, and opportunities.

Read the full report: https://www.reportlinker.com/p05773305/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original here:

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%...

The New Report Titled as Stem Cell Therapy Market published by Global Marketers, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Stem Cell Therapy Market with detailed market segmentation by solution, security type, application and geography. The Stem Cell Therapy Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Stem Cell Therapy Market are:

Celgene CorporationOsiris Therapeutics, Inc.Pharmicell Co., LtdMEDIPOST Co., Ltd.Promethera BiosciencesFibrocell Science, Inc.Holostem Terapie Avanzate S.r.l.Cytori TherapeuticsNuvasive, Inc.RTI Surgical, Inc.Anterogen Co., Ltd.RTI Surgical, Inc

The Stem Cell Therapy Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Stem Cell Therapy Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/57925

The Type Coverage in the Market are:

Adult Stem CellsHuman EmbryonicInduced Pluripotent Stem CellsVery Small Embryonic Like Stem Cells

Market Segment by Applications, covers:

Regenerative MedicineDrug Discovery and Development

Some Major TOC Points:

Chapter 1. Stem Cell Therapy Market Report Overview

Chapter 2. Global Stem Cell Therapy Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Stem Cell Therapy Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Stem Cell Therapy Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

Key questions Answered in this Stem Cell Therapy Market Report:

What will be the Stem Cell Therapy Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Stem Cell Therapy Market summary

Economic Impact on the Industry

Stem Cell Therapy Market Competition in terms of Manufacturers

Stem Cell Therapy Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

Read the original post:

Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 - Jewish...

Lets begin with, why research is important for Stem Cell Therapy Market? It is always important because it gives direction to deal with a specific problem. Report Ocean has recently published a market research report on the Stem Cell Therapy Market which will provide you a leading direction of Stem Cell Therapy Market. This research report keenly focusses on development status and recent trends of the Stem Cell Therapy Market, along with competitive landscape, supply chain, market dynamics (opportunities, restraints, and drivers), government policies and opportunities.

The Stem Cell Therapy Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

COVID 19 Impact on Stem Cell Therapy Market

This research study also includes the analyses related to the impact of Covid-19 on the Stem Cell Therapy Market. The global impacts of the coronavirus disease 2019 (COVID-19) may significantly affect the growth of the Stem Cell Therapy Market in near future. As per the experts viewpoints, it affects the global economy in 3 major ways:

By directly affecting demand and production chain

By creating market disturbance and supply chain

By impacting the firms financially and influencing the financial markets

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai26603

Competitive Landscape:

Key players in the global Stem Cell Therapy market covered in Chapter 4:AnterogenCaladriusRTI SurgicalBIOTIMEOsiris TherapeuticsPharmicellAlloSourceMEDIPOSTJCR PharmaceuticalsBrainStorm Cell TherapeuticsHolostem Terapie AvanzateAdvanced Cell TechnologyNuVasive

In this chapter will provide you a complete description of competitors and their relative position in Stem Cell Therapy Market. We will provide you the information about major players, their products, prices, market share, current strategies and main strengths and weaknesses. In this competitive world, it is indispensable to understand who the rivals are and how they usually perform with the purpose of improving its own market position. Direct and indirect competitors should be identified and analyzed. This valuable information will support decision makers when defining and evaluating company strategies.

Market Segmentation:

For a business to grow, you always need to look at the specific group of consumers. It also helps you to avoid the cost of advertising and distributing to a mass market. In this section, we mainly focused on subdivision of the Stem Cell Therapy Market into compatible subsections of customers where any subsection may be selected as a market target to be reached with a unique marketing mix

Geographically, the report includes the detailed research on market share, growth rate, consumption, production, revenue and forecast of the following regions:

United States

Central and South America (Brazil, Mexico, Colombia)

Europe (Germany, UK, France, Italy, Spain, Russia, Poland)

China

Japan

India

Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain of Stem Cell Therapy Market

Value Chain Status

Stem Cell Therapy Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Stem Cell Therapy Market

Labor Cost of Stem Cell Therapy Market

Labor Cost of Stem Cell Therapy Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Stem Cell Therapy Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Stem Cell Therapy Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Stem Cell Therapy Market Industrial Chain Analysis

Raw Materials Sources of Stem Cell Therapy Market major Players in 2019

Downstream Buyers

Stem Cell Therapy Market Forecast

Stem Cell Therapy Market Sales, Revenue and Growth Rate

Stem Cell Therapy Market Production, Consumption, Export and Import Forecast by Region

Stem Cell Therapy Market Production, Revenue and Price Forecast by Type

Stem Cell Therapy Market Consumption Forecast by Application

Stem Cell Therapy Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai26603

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

More:

Stem Cell Therapy Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2026 - Cole of...

LEXINGTON,Mass., July 21, 2020 /PRNewswire/ --Agenus Inc.(NASDAQ: AGEN), an immuno-oncology(I-O) companywith apipelineofimmunecheckpointantibodies, adoptive cell therapies and cancer vaccines,announcedtoday that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit Therapeutics Day on a Panel entitled Pursuing Curative Cell Therapy Approaches.

Date: Tuesday, July 21, 2020

Time: 3:00 PM 4:00 PM ET

Title: Pursuing Curative Cell Therapy Approaches Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah). Participants in the panel include AgenTus Therapeutics, a biotech company and subsidiary of Agenus Inc. developing new cancer treatments, including AGENT-797, an early unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a cell therapy company developing novel cell therapies including MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies Company, a biotech company developing oncology drugs including APC HPV, an autologous based therapy for several types of cancer.

Agenus Inc.Jennifer Buell, Ph.D. President and Chief Operating Officer Manuel Hidalgo, M.D. Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian

Excision BioTherapeuticsDaniel Dornbusch - Chief Executive Officer

Pluristem Therapeutics (PSTI)Racheli Ofir Vice President of Research & IP

About AgenTus Therapeutics, Inc.AgenTus Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough allogeneic iNKT cells in the unmodified and modified with engineered receptors, such as T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge the human immune system cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations inLexington, MAandCambridge, UK. For more information, please visitwww.agentustherapeutics.com.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:Agenus Inc.Jennifer Buell, PhD781-674-4420[emailprotected]

SOURCE Agenus Inc.

More here:

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit - PRNewswire

Global GMP Cell Banking Services Market: Overview

A burgeoning pharmaceutical industry hard-pressed to find treatments and cures for various chronic and other ailments has given rise to the concept of cell banking. With limited capacity to store cells required for research in the field of regenerative medicines, somatic cell therapy, gene therapy, and tissue-engineered products they are increasingly outsourcing it to other entities specializing in it.

Read Report Overview - http://www.transparencymarketresearch.com/gmp-cell-banking-services-market.html

GMP basically stands for Good Manufacturing Practice. A recent report on GMP cell banking services finds that the market is set to rise in the near term with the capacity constraints being faced by the pharmaceutical manufacturing companies and medical research institutes.

An upcoming report on the global GMP cell banking services market by Transparency Market Research attempts to examine in depth the factors molding it. It studies both the market specific factors and macro fundamentals stoking or hindering market growth. The report also segments the GMP cell banking services market based on different parameters such as applications and geography. It then deep dives into each sector to understand which ones hold out maximum promise. The report also tries to figure out the current and future size of the market with respect to revenue generation.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50559

Global GMP Cell Banking Services Market: Key Trends

A cell bank comprises of a storage facility for cells extracted from different body fluids and organ tissue so that they can be used in the future. Stored cells contain detailed characterization of the cell line thereby decreasing chances of cross contamination. And GMP cell banking services consists of outsourcing gathering, storing, characterization, and testing facilities of cell lines, tissues, and cells. The report predicts that the rising popularity and subsequent demand for stem cell therapies would provide a major boost to the global GMP cell banking services market.

As per the TMR report, the global GMP cell banking services market is also being boosted by the development of cutting-edge preservation technologies and surging research in cell line development. However, complexity of the entire procedure and inconsistent demand is dampening market growth to an extent.

Request for Analysis of COVID19 Impact on GMP Cell Banking Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=50559

Depending upon the cell type, the global GMP cell banking services market can be segmented into microbial, mammalian, yeast, insect, stem cell, and avian, among others. Among them, the segment of mammalian currently has a significant share in the market. It generates most of the revenue and would probably rise at a healthy clip in the years to come. Meanwhile, the microbial segment is predicted to emerge as the most attractive in the upcoming years.

Global GMP Cell Banking Services Market: Regional Outlook

The global GMP cell banking services market is spread across North America, Europe, Asia Pacific, and the Middle East and Africa. North America, among them, is considered one of the attractive GMP cell banking services market with the mammalian cell type segment generating most of the revenue. The segment has also been generating substantial revenue in the Asia Pacific GMO cell banking services market. In fact, the Asia Pacific market is seeing solid rise because of the shift of research and development activities in the region from North America and Europe.

Pre Book GMP Cell Banking Services Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=50559&ltype=S

Global GMP Cell Banking Services Market: Competitive Dynamics

The global GMP cell banking services market is fragmented in nature. This is because of the presence of several companies offering a range of services in it. This also limits their global outreach and localizes competition. Some the key players among them profiled in the report include WuXi AppTec, Eurofins Scientific, Charles River Laboratories International, Inc., Lonza Group Ltd., and SGS Ltd.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read the original here:

GMP Cell Banking Services Market: Subsequent demand for stem cell therapies would provide a major boost to the market - BioSpace

TORONTO, July 20, 2020 /PRNewswire/ --Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.

Notch is applying its scalable Engineered Thymic Niche (ETN) technology platform to develop homogeneous and universally compatible, stem cell-derived T cell therapies. To date, Notch has assembled a world-class scientific team and built a fully integrated, tightly controlled platform for generating and editing immune cells from clonal stem cells to enable development of a broad range of T cell therapeutics. Notch has also entered into a partnership with Allogene Therapeutics (NASDAQ: ALLO) to apply Notch's proprietary ETN platform to develop CAR-targeted, induced pluripotent stem cell (iPSC)-derived, off-the-shelf T cell or natural killer (NK) cell therapies for hematologic cancer indications.

"We have a clear goal at Notch: To create universally compatible, safe, and effective immunotherapies with the capability to treat thousands of patients from a single manufacturing run," said David Main. "The company has an internationally recognized team, a groundbreaking technology positioned to redefine and expand the clinical and commercial potential of cell therapy, and has already attracted a leading corporate partner. This is an exciting time to join and lead the company, which is now strongly positioned to advance our own pipeline of products as we also pursue additional partnering opportunities."

"We have spent the past year building a leading company developing next-generation, off-the-shelf immunotherapies driven by outstanding science and focused execution," said Ulrik Nielsen, Ph.D., Chairman of Notch. "David provides Notch with a proven industry leader and strategic thinker who has extensive experience driving and financing biotech innovation from early-stage research through commercial readiness. We are excited to bring in such outstanding leadership that is ideally suited to lead the company as it continues to advance its new class of off-the-shelf T cell therapy products."

Mr. Main is a highly experienced biopharmaceutical executive who brings to Notch more than 30 years of industry leadership experience with a strong track record of value creation and company growth. Most recently, as co-founder, Chairman, and CEO of Aquinox Pharmaceuticals, Mr. Main oversaw the advancement of the company's lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private to a NASDAQ-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, Mr. Main served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT.

About Notch Therapeutics (www.notchtx.com)Notch is an immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of cancer and immune disorders. Notch's technology platform uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and has the potential to deliver safer, consistently manufactured and more cost-effective cell immunotherapies to patients. At the core of Notch's technology is the synthetic Engineered Thymic Niche (ETN) platform, which precisely controls the expansion and differentiation of stem cells in a process suitable for large-scale manufacturing, delivering fully defined, consistent, feeder-free and serum-free T cells that can be genetically tailored for any T cell-based immunotherapeutic application. This technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

Notch Therapeutics

Read more:

Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell...

Data Bridge Market Research has recently published the Global research Report TitledAutologous Stem Cell and Non-Stem Cell Based Therapies Market. The study provides an overview of current statistics and future predictions of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Order a Free Sample Copy of thisAutologous Stem Cell and Non-Stem Cell Based Therapies Market Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

List of Companies Profiled in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report are:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Major Regions as Follows:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trendsand Forecast to 2026

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideAutologous Stem Cell and Non-Stem Cell Based Therapies market.

How Does This Market Insights Help?

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart):https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

Why choose us:

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Go here to see the original:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis & Technological Innovation - Jewish Life News

Trending Cancer Stem Cell Therapy Market 2020: COVID-19 Outbreak Impact Analysis

Chicago, United States ,The report entitled Global Cancer Stem Cell Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 released byReport Hive Researchcomprises an assessment of the market which provides the real-time market scenario and its projections during 2020 to 2025 time-period. The report offers an understanding of the demographic changes that took place in recent years. The report presents an analysis of market size, share, growth, trends, statistical and comprehensive facts of the global Cancer Stem Cell Therapy market. This research study presents informative information and in-depth evaluation of the market and its segments based totally on technology, geography, region, and applications.

The report highlights several significant features of the global Cancer Stem Cell Therapy market encompassing competitive landscape, segmentation analysis, and industry environment. It shows the scope of the market and a brief overview of the definition and description of the product or service. The potential factors that can bring the market to the upward direction have been mentioned in the report. With this report, companies, as well as individuals interested in this report, will get proven valuable guidelines and direction so that they consolidate their position in the market.The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Cancer Stem Cell Therapyindustry. Growth of the overall Cancer Stem Cell Therapymarket has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

>>>>To know How COVID-19 Pandemic Will Impact This Cancer Stem Cell Therapy Market| Download PDF Sample copy of the Report

>>>>The study encompasses profiles of major companies operating in the global Cancer Stem Cell Therapy Market. Key players profiled in the report include: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Drivers And Risks:The report covers the basic dynamics of the global Cancer Stem Cell Therapy market. It scrutinizes several data and figures, and numerous volume trends. A number of potential growth factors, risks, restraints, challenges, market developments, opportunities, strengths, and weaknesses have been highlighted. Another factor affecting market growth has also been included in the report.

Analysis of Global Cancer Stem Cell Therapy Market By Type: Autologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOthers

Analysis of Global Cancer Stem Cell Therapy Market By Application: HospitalClinicMedical Research InstitutionOthers

Regional Analysis:The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global Cancer Stem Cell Therapy market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Regional coverage:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global Cancer Stem Cell Therapy market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Cancer Stem Cell Therapy market.

Chapter 2: Evaluating the leading manufacturers of the global Cancer Stem Cell Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4: Presenting global Cancer Stem Cell Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

>>>>Get Full Customize report @ https://www.reporthive.com/request_customization/2360734

In this report, Leading players of the global Cancer Stem Cell Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Cancer Stem Cell Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Cancer Stem Cell Therapy Market. It also provides useful recommendations for new as well as established players of the global Cancer Stem Cell Therapy Market.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2360734

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: : https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Read more:

Current Trend: Global Covid-19 impact on Cancer Stem Cell Therapy Market 2020 Size, Growth Opportunities, Research Analysis and Forecast to 2025 |...

NK Cell Therapy and Stem Cell Therapy Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global NK Cell Therapy and Stem Cell Therapy Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

Report Overview: This report covers an analysis of the global NK Cell Therapy and Stem Cell Therapy Market for the forecast period 2020-2026. It unravels that the market is set to register steady growth rate in the coming years. The valuation of the global market is covered for facilitating a comparative study of the past and future data. It also offers a detailed segmental assessment of the market based on different parameters.

Leading Key Players:Chipscreen BiosciencesInnate Pharma SAOsiris TherapeuticsChiesi PharmaceuticalsMolmedJCR PharmaceuticalAltor BioScience CorporationAffimed NVTakeda PharmaceuticalPharmicellMedi-postNuVasiveAnterogen

This analysis includes a detailed share analysis of the key players. It also unveils the growth trajectories of the NK Cell Therapy and Stem Cell Therapy Market participants along with their current statuses and key developments. The growth strategies employed by these players are also assessed in the report and are prognosticated to facilitate study of the competitive landscape of the global Artificial Heart Valve Market.

Get Free Sample [emailprotected] https://www.algororeports.com/sample-request/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

Drivers and Restraints: The factors that are supposed to lead the expansion of the global market are highlighted in the assessment. The market factors are assessed and analyzed to understand their impact on the growth curve. Similarly, the factors that are presumed to restrain the growth of the market are also studied in the report.

Regional Analysis: The regions covered for the evaluation of the global NK Cell Therapy and Stem Cell Therapy Market are

North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The analysis of these regional segment is followed by a country-level analysis of each for every region. A comparative study of the segments is offered with the inclusion of valuation for every segment on both country and regional level.

Method of Research: The assessment leverages advanced and robust methodologies to provide fact-based actionable insight into the market. Key market divergences are analyzed in the report for deriving accurate information regarding the growth trajectory of the market. These market divergences identified in the research process are current status of the market, ongoing industry trends, past data, latest developments, etc. Cutting-edge data analytical tools are employed for the filtration, validation, and authentication of data collected from primary and secondary research sources. The inputs are collected from credible sources, including but not limited to, paid database services, interviews with stakeholders across the value chain (MDs, CEOs, VPs,etc.), SEC filings, surveys, and whitepaper references among others. Zero deviation from facts is ensured with the utilization of a multi-layer verification process. It also assures adherence to the highest standards of data mapping and value extrapolation. Top-down and bottom-up approaches are executed to authenticate the accuracy of the quantitative data provided in the report.

CONTENTS

ENQUIREY TO BUY REPORT@ https://www.algororeports.com/enquiry/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

About Us:

AlgoroReportsis one of the most significant database of online market researches and intelligence reports and services. The online portal for marketing research deals with access to global market data and assists in providing expert insights and exposure on global companies, industries, products and trends. AlgoroReports Consists of a highly motivated team of young and experienced individual focused on providing clients expert information they need.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

Website: https://www.algororeports.com/

Ph: +1-352-353-0818 (US)

See the original post:

NK Cell Therapy and Stem Cell Therapy Market 2020-26, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future...

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2020 to 2026. Increasing prevalence of chronic diseases and adaptation of advanced technology are driving the market growth. However high cost of the therapy might restraint the market growth

For Sample Copy of this Report @ https://www.orianresearch.com/request-sample/1131253

What You Can Expect From Our Report:

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2020 @ https://www.orianresearch.com/checkout/1131253

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Autologous Stem Cell and Non-Stem Cell Based Therapies Market report @ https://www.orianresearch.com/enquiry-before-buying/1131253

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Outlook

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market By End User

5 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Type

6 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

More here:

New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers...

New Study on the Global Stem Cell Therapy Market by PMR

PMR recently published a market study that sheds light on the growth prospects of the global Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, a methodical and systematic approach adopted by the analysts while curating the market study ensures that the presented study adds value to the business of our customers. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Stem Cell Therapy market.

As per the report, the global Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the stipulated timeframe owing to a range of factors including, favorable government policies, and growing awareness related to the Stem Cell Therapy , surge in research and development and more.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3253

Resourceful insights enclosed in the report:

Competitive Outlook

The competitive outlook section provides valuable information related to the different companies operating in the current Stem Cell Therapy market landscape. The market share, product portfolio, pricing strategy, sales and distribution channels of each company is discussed in the report.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3253

Regional Assessment

The presented market study touches upon the market scenario in different regions and provides a deep understanding of the influence of micro and macro-economic factors on the prospects of the market in each region.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3253

The market report addresses the following queries related to the Stem Cell Therapy market:

Read the rest here:

Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 - Jewish Life News

Empirica Therapeutics, a startup co-founded by Donnelly Centre investigatorJason Moffathas beenacquired by Century Therapeutics, a U.S. based company developing off-the-shelf cell therapy products for cancer.

Century will develop Empiricas proof-of-principle treatment for glioblastoma, an aggressive form of brain cancer, into therapy that can be tested on patients.

Moffat co-founded Empirica in 2018 with Dr. Sheila Singh, professor in the department of surgery at McMaster University, to leverage their combined expertise in cell engineering, functional genomics and brain tumour modelling. The teams recently demonstrated the potential of CAR-T cell therapy, in which immune cells are instructed to kill tumour cells, for the treatment of glioblastoma in preclinical models, as published in a May 2020Cell Stem Cellpaper.

Recent advances in immunotherapy have offered hope to patients with previously untreatable cancers, says Moffat, a professor of molecular genetics at U of T and the Canada Research Chair in Functional Genomics of Cancer who served as Empiricas chief scientific officer. We hope that our approach of specifically targeting glioblastoma cells with CAR-T therapy will give the patients a better quality of life and increase their chances of survival.

Philadelphia-based Century Therapeutics will further develop this type of treatment for patients. Backed by Bayer, Fujifilm, and Versant Ventures, the company specializes in developing cell therapies from induced pluripotent stem cells (iPSCs) that have been genetically engineered to avoid immune rejection. Century is working to harness the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. The companys CEO, Lalo Flores, acknowledged Empiricas deep expertise and unique capabilities that will accelerate their efforts to develop iPSC derived immune effector cell products designed to treat brain cancer.

Chimeric antigen receptor T cell (CAR-T) therapy involves genetically engineering a patients immune T cells to target and bind to a specific protein present on cancer cells directly and eliminate them. Centurys technology skirts the need to collect patients own immune cells thanks to its ability to manufacture off-the-shelf T cells that can be implanted without rejection.

Our team is excited to become part of Century Therapeutics, whose iPSC-derived allogeneic cell therapy platform is creating promising treatments for patients who need them most, says Dr. Singh, who is also a Canada Research Chair in Human Cancer Stem Cell Biology and served as Empiricas chief executive officer.

Now known as Century Therapeutics Canada, the new subsidiary will be based at McMaster Innovation Park.

Empiricas first CAR-T program was focused on a protein called CD133, which was the first brain tumor initiating cell marker discovered by Singh while a PhD student at the University of Toronto. Subsequent work by both the Singh and Moffat groups led to a deeper functional understanding of CD133 and an antibody that proved useful for marking cells for therapy.

When used in mice with human glioblastoma, CD133-targetting CAR-T therapy was considered a success due to reduced tumor burden and improved survival. These pre-clinical results were partly supported by a Terry Fox Research Institute New Frontiers Program Project Grant awarded to a multidisciplinary team of scientists including Singh and Moffat.

Glioblastoma is the most common and aggressive form of brain cancer owing to tumour heterogeneity at the molecular level and its ability to evolve into new forms that resist therapy. Standard treatment involves surgery, radiation and chemotherapy but most patients relapse within seven to nine months, while median survival between diagnosis and death has not extended beyond 16-20 months over the past decade.

CAR-T will be delivered in recurrent glioblastoma patients after Moffat and Singhs teams found that a population of CD133 positive glioblastoma cells remain following initial treatment.

If we can hit those cells at minimal disease, we should buy the patient more time, says Moffat. And hopefully well find a way to figure out how to combine multiple CAR-Ts; for example, by combining CD133 and other targets to potentially even cure the disease.

Empirica Therapeutics was supported by investments from U of Ts strategic partners, the Centre for Commercialization of Antibodies and Biologics and the Centre for Commercialization of Regenerative Medicine.

We are proud to have been involved with the launch and growth of Empirica, stated Rob Verhagen, former CEO of CCAB. The outcome with Century marks another stride in building a productive life science industry at U of T and McMaster and we look forward to seeing this valuable research benefiting patients in the future. The startup was also supported by the McMaster Industry Liaison Office and the Ontario Bioscience Innovation Organization through important connections to relevant business networks and partners.

See the rest here:

U of T spin-off Empirica Therapeutics acquired by US firm - News@UofT

Latest Study on the Global Rheumatoid Arthritis Stem Cell Therapy Market

The recently published report by Transparency Market Research on the global Rheumatoid Arthritis Stem Cell Therapy market offers resourceful insights pertaining to the future prospects of the Rheumatoid Arthritis Stem Cell Therapy market. The underlying trends, growth opportunities, impeding factors, and glaring market drivers are thoroughly studied in the presented report.

As per the report, the global Rheumatoid Arthritis Stem Cell Therapy market is projected to grow at a CAGR of ~XX% and exceed the value of ~US$ towards the end of 2029. Moreover, an in-depth analysis of the micro and macro-economic factors that are anticipated to influence the trajectory of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period (2019-2029) is included in the report.

Critical Insights Related to the Rheumatoid Arthritis Stem Cell Therapy Market in the Report:

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segments

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Important queries related to the Rheumatoid Arthritis Stem Cell Therapy market addressed in the report:

Why Choose Rheumatoid Arthritis Stem Cell Therapy Market Report?

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Excerpt from:

Rheumatoid Arthritis Stem Cell Therapy Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2018 to 2028 - 3rd...

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/24200

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Orange County Hair Restoration Center

Colorado Surgical Center&, Hair Institute

Evolution Hair Loss Institute

Hair Sciences Center of Colorado

Hair Transplant Institute of Miami

Anderson Center for Hair

Virginia Surgical Center

Savola Aesthetic Dermatology Center

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Platelet Rich Plasma Injections

Stem Cell Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies for each application, including

Dermatology Clinics

Hospitals

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/24200

Major Point of TOC:

Chapter One: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

Chapter Two: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Player

Chapter Three: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Type

Chapter Four: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Application

Chapter Five: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Sales Channel

Chapter Six: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Region

Chapter Seven: Profile of Leading Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players

Chapter Eight: Upstream and Downstream Analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Chapter Nine: Development Trend of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/24200

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

Excerpt from:

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -...

When a patient with cancer hears there isn't much left that doctors can do, it always stays fresh in the mind.

Doug Olson was first diagnosed with chronic lymphocytic leukemia (CLL) over 20 years ago, in 1996. For several years, his doctors used the watch-and-wait approach. But then his cancer progressed and needed treatment. By 2010, it had mutated so much that it no longer responded to standard therapy.

He was rapidly running out of options. Back then, the only treatment left was a bone marrow transplant. Without one, his doctors said, he would have 1 or 2 years left to live.

"I was really trying to avoid a bone marrow transplant. You're playing your last card if that doesn't work. It's a pretty rough procedure," Olson told Medscape Medical News.

Looking back, Olson counts himself as lucky for being in the right place, at the right time, with the right doctor. His oncologist was David Porter, MD, the principal investigator on a trial at the University of Pennsylvania that was investigating a brand new approach to treating cancer: chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy uses a patient's own T cells engineered to express a receptor that targets proteins on cancer cells. CAR T cells are considered "living drugs" because they expand inside the body and stick around for years maybe for a lifetime to fight the cancer if it tries to come back.

"I was certainly intrigued by the approach. It had worked in mice, and it was the sort of thing that looked like it would work," Olson recalled.

Science is not a foreign language to Olson. He holds a PhD in medicinal chemistry, spent most of his career in the in vitro diagnostics industry, and currently acts as chief executive officer of Buhlmann Diagnostics Corp.

So he read the clinical protocol for the first in-human trial of CAR T cells and agreed to become patient number two.

Olson's T cells were harvested, engineered to attack the CD19 antigen found on malignant and normal B lymphocytes, and then were expanded into millions in the lab. After undergoing preconditioning with chemotherapy to minimize rejection and boost the CAR T cells' expansion inside the body, he received several infusions of the new therapy over the course of 3 days.

Nothing really happened for 2 weeks. Then he developed severe flu-like symptoms so bad that he was hospitalized.

Ironically, getting sick was a sign that the CAR T cells were working. Olson was experiencing one of the main short-term effects of CAR T-cell therapy: cytokine release syndrome. Symptoms include extremely high fevers and dangerous drops in blood pressure that can potentially cause end-organ damage.

In the early trials of these products, some patients experienced such a severe reaction that they needed intensive care, and some died. With increasing clinical experience, doctors have learned to control the reaction with the use of steroids and interleukein-6 inhibitors such as tocilizumab (Actemra).

Fortunately for Olson, the reaction passed, and he was eventually discharged.

Then the "aha moment" happened. Four weeks after receiving the CAR T cells, Olson found out that he was cancer free.

"It still gives me shivers," he said. "Dr Porter said, 'Your bone marrow's completely free. We just can't find a cancer cell anywhere.' "

The remission has lasted, and it is now 10 years later.

Long-term data have been accumulating for these novel therapies since Olson's treatment in 2010. This is particularly important for CAR T-cell therapy, because of its longevity. Because these are living cells and are expected to persist in the body for years, there is great interest in longer-term data, especially the risks for toxicity.

The FDA requires clinical follow-up for at least 15 years for patients treated with CAR T-cell therapy or any other genetically modified cells.

So far, most of the experience with CAR T cells comes from anti-CD19-directed therapy, which has shown "remarkable" remission rates in the 50% to 85% range, said Nirali Shah, MD, head of the hematologic malignancies section of the Pediatric Oncology Branch at the National Cancer Institute (NCI).

The most recent results presented at this year's annual meeting of the American Society of Clinical Oncology support earlier efficacy data, she noted. In the longest follow-up to date, researchers reported remissions lasting over 9 years in patients with relapsed/refractory B-cell lymphoma or CLL treated with Kite's axicaptagene cilleucel (Yescarta), one of two anti-CD19-directed CAR T-cell therapies approved by the FDA in 2017 (the other is Novartis' tisagenlecleucel [Kymriah]).

This study included 43 patients and showed an overall remission rate of 76%. Complete remission was achieved in 54% of patients, and 22% had partial remission.

The other focus is long-term safety. Although some of the long-term adverse effects are known and are manageable, others fall into the theoretical realm. In early May 2020, the NCI held a multidisciplinary virtual conference on CAR T-cell therapy "to encourage collaborative research about the subacute and potentially long-term toxicity profile of these treatments."

"We know just a little at this point about late- and long-term effects of CAR-T therapy, because we are relatively early in the era of CAR T cells," said Merav Bar, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington.

What is known is that B-cell aplasia represents the most common long-term adverse effect of CAR T-cell therapy. B-cell aplasia results when anti-CD19 CAR-T therapy wipes out healthy B cells as well as the malignant ones responsible for leukemia/lymphoma.

As major players in the immune system, B cells are a key defense against viruses. So B-cell aplasia represents a very specific type of immunosuppression. It is generally less severe than immunosuppression that occurs after organ transplant, which hits the immune system pretty much across the board and carries a much higher risk for infection.

The main concern is what happens when someone with B-cell aplasia encounters a new pathogen, such as SARS-CoV-2.

After infection, B cells generate memory cells, which are not killed off by anti-CD19 therapy and that stick around for life. So a patient such as Olson would still make antibodies that fight infections they experienced before receiving CAR-T therapy, such as childhood chickenpox. But now they are unable to make new memory cells, so these patients receive monthly immunoglobulin infusions to protect against pathogens they have not previously encountered.

Olson takes this in stride and says he isn't overly worried about COVID-19. He follows the recommended precautions for a man his age. He wears a mask, washes his hands frequently, and tries to maintain social distancing. But he doesn't stay locked up in his New Hampshire home.

"I took the attitude when I was diagnosed with cancer that I'm going to live my life," he said. "Quality of life to me is more important than quantity."

Another problem is the possibility of neuropsychiatric toxicity. Past studies have reported a wide range of such toxicities associated with CAR T-cell therapy, including seizures and hallucinations. Most have occurred early in the course of treatment and appear to be short-lived and reversible. However, there remain questions about long-term neuropsychiatric problems.

In a long-term study of 40 patients with relapsed/refractory CLL, non-Hodgkin lymphoma, and ALL, nearly half of patients (47.5%, 19/40) self-reported at least one clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty) 1 to 5 years after anti-CD19 CAR T-cell therapy. In addition, 37.5% (15/40) self-reported cognitive difficulties.

"Patients with more severe neurotoxicity showed a trend for more cognitive difficulties afterwards," said Bar, senior author of the study.

However, teasing out the role that CAR T-cell therapy plays in these problems poses a challenge. All of these patients had been heavily pretreated with previous cancer therapy, which has also been associated with neuropsychiatric problems.

"So far, we don't know what caused it," Bar said. "Nevertheless, people need to pay attention to neuropsychiatric symptoms in CAR T-cell therapy. It is important to continue to monitor these patients for these issues."

Another potential problem is graft-vs-host disease (GVHD). This is not uncommon after hematopoietic stem cell transplants. It develops when the donor T cells view antigens on healthy recipient cells as foreign and attack them.

For patients who are treated with CAR T cells, GVHD is mostly a concern among individuals who have previously had a transplant and who are already at increased risk for it.

In a study of late effects among 86 adults treated with anti-CD19 CAR T cells for relapsed/refractory non-Hodgkin lymphoma, Bar and colleagues found that GVHD occurred only among patients who had received a previous donor stem cell transplant. Of these, 20% (3/15) developed GVHD about 28 months after CAR-T therapy.

"The data for CAR T cells causing GVHD really hasn't shown that it's a huge problem, although we have seen it and are continuing to monitor for it," the NCI's Shah commented to Medscape Medical News.

A range of other long-term adverse effects have been reported with CAR-T therapy, including prolonged cytopenias (reduced mature blood cells), myelodysplasia (bone marrow failure), and second malignancies.

In the study with the longest follow-up to date, 16% (7/43) of patients developed second malignancies, which is comparable to data from Bar's study in Seattle (15%, 13/86). The researchers in this study consider this rate to be no higher than expected: these patients had already received extensive chemotherapy, which increases the risk for other cancers, they point out.

However, this brings up theoretical concerns about the long-term effects of gene modification. CAR T cells are engineered using retroviruses (mainly lentiviruses), which randomly insert the CAR genes into the host genome. Doing so may cause mutations that could promote cancer. These lentiviruses also carry the theoretical risk of becoming capable of viral replication once inside the body.

To address these concerns, viruses used to engineer CAR T cells go through comprehensive safety testing. After therapy, patients are checked every few months during the first year and annually after that.

So far, there have been no reports of cancers associated with CAR T-cell therapy.

"Any type of cancer is a very theoretical risk," Bar told Medscape Medical News. "Most likely the malignancies in our study were related to prior treatment that the patients received. None of them had any evidence of replication-competent lentivirus, or any other evidence that the malignancies were related to the CAR T cells."

Another theoretical concern is the possibility of new-onset autoimmune disease, although, once again, no cases have been reported so far.

"We think of it as a theoretic possibility. Whenever you jack up the immune system, autoimmune disease is a potential risk," said Carl June, MD, director of the Center for Cellular Immunotherapies at the University of Pennsylvania.

June was the coprincipal investigator of the trial in which Olson participated. He is also the inventor on patents for CAR T cells licensed by the University of Pennsylvania to Novartis and Tmunity and is a scientific founder with equity in Tmunity.

Still, autoimmunity could occur, and scientists are looking out for it.

"We are continuing to be vigilant in our monitoring for autoimmune disease," Shah added. "We've been doing CAR T-cell therapy since 2012, and I think we have yet to see true autoimmunity beyond GVHD."

In the 10 years since Olson received CAR T-cell therapy, an entire industry has sprung up. Over 100 companies worldwide are now developing CAR T-cell therapies targeting various antigens. These therapies are directed at about 60 different tumor types, including solid tumors. Nearly 200 clinical trials are underway, though most are still in early stages: as of September 2019, only 5% had reached phase 3.

Clinical data show promising results for CAR T-cell therapy directed against CD22 (overexpressed on ALL cells), and BCMA (found on almost all multiple myeloma cells). Yet questions remain as to whether CAR T cells will be as effective if they target antigens other than CD19 or cells other than B lymphocytes. One of the biggest research questions is whether they will be effective against solid tumors.

One research avenue being watched with great interest is the development of universal CAR T cells. So far, such products are at very early stages of development (phase 1 trials), but they are attractive because of the potential advantages they offer over bespoke CAR T cells. Automating the process holds the promise of immediate availability, standardizing production, expanding access, and lowering costs. And because the T cells for this universal product come from healthy donors, they may function better than T cells that have been battered and bruised by past cancer treatments, or even the cancer itself.

However, precisely because they are developed from healthy donor T cells, universal CAR T cells may pose increased risk for GVHD. Scientists are trying to get around this problem by engineering universal CAR T cells that lack the T-cell receptor involved in GVHD.

There are also other concerns. Nature has a penchant for mutation. Engineering CAR T cells without T-cell receptors means the body may no longer detect or reject a universal CAR T cell if it goes rogue. Also, gene insertion in universal CAR-T therapy is targeted rather than random (as in bespoke CAR T cells), which could create off-target effects. Both issues create a theoretical risk of such products inducing an untreatable CAR T-cell therapyassociated cancer.

"The theoretic risk with universal cells is that their safety profile may not be as good for long term," June commented.

From that first trial in which June and Porter used CAR T cells, two of three patients they treated are still alive 10 years later.

Olson is one of these two, and he still undergoes monitoring every 3 months to check for relapse. So far, none of his tests have shown signs of his cancer returning.

After going into remission, Doug spent the next 6 to 9 months regaining his health and strength.

"I figured if I had this amazing treatment that saved my life, I had an obligation to stay alive," he said. "I'd better not die of something like a heart attack!"

He took up long distance running and has completed six half marathons. He became involved in the Leukemia and Lymphoma Society, participating in fund-raising and helping newly diagnosed patients. Over the years, he has also given talks for researchers, people with cancer, and healthcare providers.

Doug is now 73. Today, he marvels at how rapidly the CAR-T field has progressed.

"Twenty years ago, if you had cancer, your prospects weren't nearly as good as these days. In 2010, people still didn't believe in CAR T-cell therapy," he said. "My goal always in telling my story is a message of hope."

For more from Medscape Oncology, join us on Twitter and Facebook.

The rest is here:

In Remission for 10 Years: Long-term Data on CAR-T Therapy - Medscape